Joe Pinkstone

Joe Pinkstone is a journalist at The Telegraph, covering a wide range of topics including health and science. He has reported on various issues related to medical research and advancements, as well as investigations into public health scandals such as the infected blood scandal. Pinkstone's work often highlights the impact of scientific discoveries on people's lives and explores the potential implications of new technologies.

Biography:  https://www.telegraph.co.uk/authors/j/jk-jo/joe-pinkstone/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • More than half of men reached contraception-level effectiveness by eight weeks.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Non-Hormonal Male Contraceptive Shows Promise in Reducing Sperm Production

New Non-Hormonal Male Contraceptive Shows Promise in Reducing Sperm Production

Broke On: Tuesday, 28 May 2024 Researchers at Baylor College of Medicine have developed a promising non-hormonal male contraceptive, CDD-2807, which targets the protein STK33 in testes to reduce sperm mobility and numbers without significant side effects. The compound inhibits STK33 in mice studies, suppressing sperm production without affecting other reproductive functions. A gel form of CDD-2807 applied daily to men's shoulders reached low sperm levels within 12 weeks, showing potential in clinical trials.